◀ Back to ABL1
ABL1 — MYC
Pathways - manually collected, often from reviews:
Text-mined interactions from Literome
Xie et al., Oncogene 2002
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
Jak2 is involved in
c-Myc induction by
Bcr-Abl ... In summary, our findings indicate that Jak2 mediates the increase in
c-Myc expression that is
induced by
Bcr-Abl
Clark et al., Oncology 2006
(Leukemia) :
Since
Bcr/Abl induces constitutive expression of
c-Myc , which is necessary for cell cycle transit from G1 into the S phase, we tested whether POH causes growth arrest by inhibiting expression of c-Myc
Zimmerman et al., J Virol 2008
(Cell Transformation, Viral) :
As is consistent with the ability of
v-Abl to
stimulate Myc , a transcription factor known to induce p19(Arf), Myc and Arf are induced soon after infection and p19(Arf) is expressed
Nakamura et al., Int J Cancer 2012
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
The induction of THAP11 expression by
Abl kinase inhibitors in CML cell lines and in CML derived hematopoietic progenitor cells
resulted in the suppression of
c-Myc
Sung et al., PloS one 2012
(Neoplasms) :
p150 binds to the nuclease hypersensitive element of the c-MYC promoter and
represses c-MYC transcription ... Overexpression of
p150 in human ovarian surface epithelial cells
leads to decreased expression, and downregulation to increased expression, of
c-MYC